BTIG Maintains Buy on Protagonist Therapeutics, Raises Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Julian Harrison maintains a Buy rating on Protagonist Therapeutics (NASDAQ:PTGX) and raises the price target from $41 to $51.
July 24, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Julian Harrison maintains a Buy rating on Protagonist Therapeutics and raises the price target from $41 to $51.
The raised price target and maintained Buy rating from a reputable analyst at BTIG is likely to positively impact the stock price of Protagonist Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100